Table 1 Baseline characteristics and clinical presentation of 201 children for the CHD and non-CHD cohort
From: Effect of congenital heart disease on the recurrence of cough variant asthma in children
| Characteristic | Non-CHD | CHD | P value | ||
|---|---|---|---|---|---|
| N = 134 | N = 67 | ||||
| N | % | N | % | ||
| Clinical presentation | |||||
| Age (year) | 0.99 | ||||
| 1–3 | 54 | 40.3 | 27 | 40.3 | |
| 4–6 | 38 | 28.4 | 19 | 28.4 | |
| 7–14 | 42 | 31.3 | 21 | 31.3 | |
| Sex | 0.99 | ||||
| Male | 74 | 55.2 | 37 | 55.2 | |
| Female | 60 | 44.8 | 30 | 44.8 | |
| Family history of allergies | 123 | 91.8 | 57 | 85.1 | 0.150 |
| Family history of eczema | 64 | 47.8 | 30 | 44.8 | 0.689 |
| Family history of asthma | 26 | 19.4 | 14 | 20.9 | 0.803 |
| Laboratory examination | |||||
| Elevated eosinophil ratio | 44 | 32.8 | 18 | 26.8 | 0.388 |
| Mycoplasma pneumonia positive | 69 | 51.5 | 38 | 56.7 | 0.484 |
| sIgE sensitization | 85 | 63.4 | 40 | 59.7 | 0.607 |
| Food | 70 | 52.2 | 32 | 47.8 | 0.549 |
| Aeroallergen | 84 | 62.7 | 37 | 55.2 | 0.308 |
| Treatment | 0.99 | ||||
| Fluticasone Propionate inhalation aerosol (flixotide) + salbutamol | 92 | 68.7 | 46 | 68.7 | |
| Salmeterol xinafoate and fluticasone propionate powder for inhalation (seretide) + salbutamol | 42 | 31.3 | 21 | 31.3 | |